EP1718669A4 - Identification de nouveaux epitopes ige - Google Patents

Identification de nouveaux epitopes ige

Info

Publication number
EP1718669A4
EP1718669A4 EP04779424A EP04779424A EP1718669A4 EP 1718669 A4 EP1718669 A4 EP 1718669A4 EP 04779424 A EP04779424 A EP 04779424A EP 04779424 A EP04779424 A EP 04779424A EP 1718669 A4 EP1718669 A4 EP 1718669A4
Authority
EP
European Patent Office
Prior art keywords
identification
ige epitopes
novel ige
novel
epitopes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04779424A
Other languages
German (de)
English (en)
Other versions
EP1718669A1 (fr
Inventor
Sanjaya Singh
Danyang Huang
Sek Chung Michael Fung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanox Inc
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2004/002892 external-priority patent/WO2004070010A2/fr
Application filed by Tanox Inc filed Critical Tanox Inc
Publication of EP1718669A1 publication Critical patent/EP1718669A1/fr
Publication of EP1718669A4 publication Critical patent/EP1718669A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP04779424A 2004-02-02 2004-07-29 Identification de nouveaux epitopes ige Withdrawn EP1718669A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2004/002892 WO2004070010A2 (fr) 2003-02-01 2004-02-02 Procede destine a produire des anticorps a affinite elevee
PCT/US2004/002894 WO2004070011A2 (fr) 2003-02-01 2004-02-02 Anticorps ige anti-humains a affinite elevee
PCT/US2004/024360 WO2005075504A1 (fr) 2004-02-02 2004-07-29 Identification de nouveaux epitopes ige

Publications (2)

Publication Number Publication Date
EP1718669A1 EP1718669A1 (fr) 2006-11-08
EP1718669A4 true EP1718669A4 (fr) 2007-10-10

Family

ID=34841291

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04779424A Withdrawn EP1718669A4 (fr) 2004-02-02 2004-07-29 Identification de nouveaux epitopes ige

Country Status (8)

Country Link
EP (1) EP1718669A4 (fr)
JP (1) JP2008507474A (fr)
KR (4) KR101365375B1 (fr)
CN (1) CN102702359A (fr)
AU (2) AU2004315197B2 (fr)
CA (1) CA2552999A1 (fr)
SG (2) SG149892A1 (fr)
WO (1) WO2005075504A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080241069A1 (en) * 2006-08-04 2008-10-02 Yvonne Paterson Methods and compositions for treating IgE-mediated diseases
US7833527B2 (en) * 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
AR065368A1 (es) * 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
EP2592094A1 (fr) * 2007-02-15 2013-05-15 AstraZeneca AB Elements de liaison pour molecules IgE
EP2012122A1 (fr) * 2007-07-06 2009-01-07 Medigene AG Protéines structurelles de parvovirus muté
US20100272745A1 (en) * 2007-12-21 2010-10-28 Dominique Ingrid Lemoine Vaccines for malaria
JP5209800B2 (ja) 2008-12-09 2013-06-12 ファイザー バクシーンズ エルエルシー ＩｇＥＣＨ３ペプチドワクチン
EP2575868A1 (fr) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Vaccin peptidique ige ch3
US11518818B2 (en) * 2017-01-06 2022-12-06 The Regents Of The University Of California Therapeutic anti-IgE antibodies and methods and compositions thereof
EP3773904A1 (fr) * 2018-03-26 2021-02-17 Novartis AG Procédés de traitement de l'urticaire chronique spontanée à l'aide de ligelizumab
CN117460531A (zh) 2021-06-14 2024-01-26 诺华股份有限公司 含有抗IgE抗体的药物配制品

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0263655A2 (fr) * 1986-10-03 1988-04-13 Dainippon Pharmaceutical Co., Ltd. Peptides à activité antiallergique
EP0957111A2 (fr) * 1998-04-09 1999-11-17 Idexx Laboratories, Inc. Protéines de liaison spécifiques pour le traitement des allergies canines
WO2000023477A2 (fr) * 1998-10-20 2000-04-27 University Of Sheffield Variants d'immunoglobuline
WO2000050461A1 (fr) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Epitopes ou mimotopes derives des domaines c-epsilon-3 ou c-epsilon-4 des ige, leurs antagonistes et leur utilisation therapeutique
WO2000074716A2 (fr) * 1999-06-08 2000-12-14 Smithkline Beecham Biologicals S.A. Vaccin
WO2002016409A2 (fr) * 2000-08-22 2002-02-28 Glaxosmithkline Biologicals S.A. Nouveaux composes et procede
EP1195161A2 (fr) * 2000-08-30 2002-04-10 Pfizer Products Inc. Anti-IgE vaccins
WO2002034288A2 (fr) * 2000-10-27 2002-05-02 Smithkline Beecham Biologicals S.A. Vaccin
EP1262491A2 (fr) * 2001-05-22 2002-12-04 Pfizer Products Inc. Vaccines d'IgE non-anaphylactogènes
WO2003092714A2 (fr) * 2002-04-30 2003-11-13 Glaxosmithkline Biologicals S.A. Vaccin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2219640T3 (es) * 1992-09-24 2004-12-01 Novartis Ag Anticuerpos monoclonales reformados contra un isotopo de inmunoglobulina.
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US7393529B2 (en) * 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
JP2006516408A (ja) * 2003-02-01 2006-07-06 タノックス インコーポレーテッド 高親和性抗体の生成方法

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0263655A2 (fr) * 1986-10-03 1988-04-13 Dainippon Pharmaceutical Co., Ltd. Peptides à activité antiallergique
EP0957111A2 (fr) * 1998-04-09 1999-11-17 Idexx Laboratories, Inc. Protéines de liaison spécifiques pour le traitement des allergies canines
WO2000023477A2 (fr) * 1998-10-20 2000-04-27 University Of Sheffield Variants d'immunoglobuline
WO2000050461A1 (fr) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Epitopes ou mimotopes derives des domaines c-epsilon-3 ou c-epsilon-4 des ige, leurs antagonistes et leur utilisation therapeutique
WO2000074716A2 (fr) * 1999-06-08 2000-12-14 Smithkline Beecham Biologicals S.A. Vaccin
WO2002016409A2 (fr) * 2000-08-22 2002-02-28 Glaxosmithkline Biologicals S.A. Nouveaux composes et procede
EP1195161A2 (fr) * 2000-08-30 2002-04-10 Pfizer Products Inc. Anti-IgE vaccins
WO2002034288A2 (fr) * 2000-10-27 2002-05-02 Smithkline Beecham Biologicals S.A. Vaccin
EP1262491A2 (fr) * 2001-05-22 2002-12-04 Pfizer Products Inc. Vaccines d'IgE non-anaphylactogènes
WO2003092714A2 (fr) * 2002-04-30 2003-11-13 Glaxosmithkline Biologicals S.A. Vaccin

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHANG T W ET AL: "MONOCLONAL ANTIBODIES SPECIFIC FOR HUMAN IGE-PRODUCING B CELLS A POTENTIAL THERAPEUTIC FOR IGE-MEDIATED ALLERGIC DISEASES", BIO-TECHNOLOGY (NEW YORK), vol. 8, no. 2, 1990, pages 122 - 126, XP009084134, ISSN: 0733-222X *
MACGLASHAN D W ET AL: "DOWN-REGULATION OF FCEPSILONRI EXPRESSION ON HUMAN BASOPHILS DURINGIN VIVO TREATMENT OF ATOPIC PATIENTS WITH ANTI-IGE ANTIBODY", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 158, 1997, pages 1438 - 1445, XP002930932, ISSN: 0022-1767 *
See also references of WO2005075504A1 *

Also Published As

Publication number Publication date
CN102702359A (zh) 2012-10-03
KR20070008578A (ko) 2007-01-17
KR20130088198A (ko) 2013-08-07
KR101581659B1 (ko) 2015-12-31
SG183683A1 (en) 2012-09-27
AU2004315197B2 (en) 2009-06-04
CA2552999A1 (fr) 2005-08-18
KR20140021058A (ko) 2014-02-19
JP2008507474A (ja) 2008-03-13
AU2004315197A1 (en) 2005-08-18
AU2009202408A1 (en) 2009-07-09
KR20120056297A (ko) 2012-06-01
EP1718669A1 (fr) 2006-11-08
SG149892A1 (en) 2009-02-27
KR101365375B1 (ko) 2014-02-19
WO2005075504A1 (fr) 2005-08-18
KR101562114B1 (ko) 2015-11-20

Similar Documents

Publication Publication Date Title
IL176940A0 (en) IDENTIFICATION OF NOVEL IgE EPITOPES
GB0412973D0 (en) Identification of antibody producing cells
ZA200609595B (en) Novel CIS-Imidazolines
IL179730A0 (en) Novel cis-imidazolines
EP1778618A4 (fr) Synthese de triethylenetetramines
IL211491A0 (en) 4-(benzimidazolylmethylamino)-benzamidines
TWI372750B (en) Novel hydroxy-6-heteroarylphenanthridines
EP1756092A4 (fr) Inhibiteurs novateurs de protéines rho-kinases
IL179811A0 (en) Identification of tumors
EP1869192A4 (fr) Rearrangement de l'infrastructure d'anticorps
EP1965341A4 (fr) Carte permettant une authentification
EP1711484A4 (fr) Synthese de cyanoimino-benzoimidazoles
HK1081282A1 (en) Chronograph
GB0426160D0 (en) Production of proteins
EP1718669A4 (fr) Identification de nouveaux epitopes ige
IL183106A0 (en) Production of proteins
HK1087494A1 (en) Wristwatch case
ZA200610303B (en) Novel cis-imidazolines
IL178184A0 (en) Synthesis of pyrrole-2-carbonitriles
ZA200606635B (en) Novel isoamido-substituted hydroxy-6-phenylphenanthridines
AU158223S (en) Wristwatch
GB0408865D0 (en) Novel benzoxazocines
GB0424519D0 (en) Identification of micro-organisms
GB0413479D0 (en) Novel antibodies
ZA200508325B (en) Manufacture of kerbstones

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060824

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

A4 Supplementary search report drawn up and despatched

Effective date: 20070912

17Q First examination report despatched

Effective date: 20090407

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130625